JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥33 | ¥43 | ¥34 | ¥51 |
| % Growth | -22.9% | 24.8% | -32.8% | – |
| Cost of Goods Sold | ¥12 | ¥12 | ¥9 | ¥10 |
| Gross Profit | ¥22 | ¥31 | ¥25 | ¥41 |
| % Margin | 65.2% | 72.9% | 74.1% | 79.5% |
| R&D Expenses | ¥15 | ¥11 | ¥9 | ¥7 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥13 | ¥12 | ¥12 | ¥14 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥28 | ¥24 | ¥20 | ¥21 |
| Operating Income | -¥7 | ¥8 | ¥5 | ¥20 |
| % Margin | -20.7% | 17.6% | 14.5% | 39% |
| Other Income/Exp. Net | ¥0 | -¥0 | ¥0 | -¥1 |
| Pre-Tax Income | -¥6 | ¥7 | ¥5 | ¥19 |
| Tax Expense | -¥2 | ¥2 | ¥2 | ¥5 |
| Net Income | -¥5 | ¥6 | ¥4 | ¥15 |
| % Margin | -14.4% | 12.8% | 11% | 28.4% |
| EPS | -38.43 | 44.13 | 30.34 | 117.26 |
| % Growth | -187.1% | 45.5% | -74.1% | – |
| EPS Diluted | -38.43 | 43.92 | 30.22 | 116.79 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥3 | ¥3 | ¥2 | ¥2 |
| EBITDA | -¥3 | ¥11 | ¥7 | ¥21 |
| % Margin | -8.7% | 24.6% | 21.7% | 41.9% |